Floatz logo

Reboxetine

Cerebral Stroke

Universitätsklinikum Hamburg-EppendorfSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

133 Active assets in the Cerebral Stroke cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Rivaroxaban
China National Center for Cardiovascular Diseases
Phase 4BBB

View all 50 →

Same molecule, other indications

Reboxetine is also rated in:

PainDormant
B
Indicative ·
59 / 100
View asset →
major depressive disorderDormant
B
Indicative ·
59 / 100
View asset →
depressive disorderDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →